Canada: Pharma and Medical Device Advertising in Social Media – Worth the Risk?

Copyright 2011, Blake, Cassels & Graydon LLP

Originally published in Blakes Bulletin on Intellectual Property – Social Media Series, January 2011

The use of social media to advertise regulated products, such as pharmaceuticals and medical devices, can be very powerful, but is also fraught with risk. Recently, a drug company entered into a clever but provocative partnership in the United States with a professional race car driver, who also happens to be an avid TWITTER user and diabetic. In response to the driver's request to TWEET about two insulin products made by the company, the company said he could only do so if he included the drug's generic name as well as a link to information about the drug's risks and benefits. The driver now regularly TWEETS about his insulin, a recent example being, "Saw an ad for [branded product] on TV! For [branded product] [generic name] prescribing information: [website link]".

By contrast, some companies have not fared so well with their foray into social media. Another major pharmaceutical company in the U.S. set up a FACEBOOK page that was soon flooded with postings by one disgruntled patient who claimed that the company's chemotherapy drug disfigured her because it caused permanent baldness. The patient said that she took her dispute to FACEBOOK because she had written multiple times to the company to no avail.

The company subsequently posted a disclaimer on its FACEBOOK page stating that the page is not intended as a forum for discussing products of the company or other companies and that postings containing any product discussions would be removed. Although the offending posts were removed, the public relations damage was already done.

Although social media are already crucial advertising vehicles for many companies, it has not been as widely embraced by those in the pharmaceutical and medical device industries. One reason for this is the lack of clarity on how health regulators will view certain activities. Although laws of general application apply regardless of the advertising medium used, the application of these general laws can be uncertain.

Compared to traditional media, social media are more interactive, with businesses having less control. Businesses contemplating initiatives using social media are concerned about their potential obligations and liabilities relating to the content and action of an unrelated third party.

Guidance by Regulators on Social Media Advertising

The lack of certainty on how laws are applied has many stakeholders anxiously awaiting the U.S. Food and Drug Administration's (FDA) guidance on advertising in social media. The FDA held a hearing on the "Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools" in late 2009. Interestingly, some submissions essentially stated that the key is that guidance be issued, whatever the guidance may be.

Although the FDA had been expected to release guidance by the end of 2010 on a comprehensive range of issues, it now appears that the FDA's new target is to release guidance on one issue by the first quarter of 2011.

Despite the FDA's delay, Canadian guidance specifically addressing advertising in social media will likely lag the U.S. since, although "[t]he idea of creating guidelines for the pharmaceutical industry's social media marketing projects was raised" at the April 2009 meeting between Health Canada and Canadian advertising pre-clearance agencies, no significant advance appears to have occurred.

It is interesting to note that a number of Health Canada's general advertising policies now make reference to "social media", if only to reinforce the principle that Health Canada's general advertising requirements apply regardless of the medium.

Advertising Drugs an d De vices in Social Media

The following highlights three key issues that advertisers of pharmaceuticals and medical devices should consider prior to embarking in the realm of social media, namely: (i) off-label claims; (ii) insufficient disclosure; and (iii) reporting obligations.

Given the lack of guidance from the regulators, there are many unanswered questions and how these issues will be resolved is unclear. However, set out below are some questions and factors that companies should at least consider so they can make a more informed assessment of their risks and determine the best approach in the absence of official guidance.

1. Off-Label Claims

Pharmaceutical and device companies cannot promote their products "off-label" (i.e., they cannot promote their products for an unapproved medical condition or use). Although this is clear, what is less clear is a company's obligation or responsibility when an off-label claim is made by a third party.

For example, a company might sponsor an initiative where patients, consumers or health-care professionals can post comments or questions about a particular drug or medical device. What happens if a third party makes an off-label claim about the product?

Does the company have any obligation to post a disclaimer stating that the product is not approved for the off-label condition or, alternatively, stating the approved condition, or both? Or, should the company delete the off-label claim altogether?

Alternatively, should the company have instead screened all submissions in the first place to ensure no off-label claim is ever posted? Further, should the rules vary depending on whether the forum for postings is for patients, consumers, or health-care professionals?

2. Insufficient Disclosure

Advertising of health products typically requires the disclosure of certain information. Certain drug advertising, for example, requires the disclosure of "fair and balanced information about the benefits and the risks".

However, with certain social media formats, space limitation is a major issue. For example, TWITTER limits TWEETS to 140 characters. Does a requirement to disclose the risks of a product mean that the actual risks must be spelled out or would a link to a website spelling out those risks be sufficient?

The FDA has taken some action which is instructive. It recently issued a notice of violation letter to a major pharmaceutical company regarding its use of the Facebook Share widget on the company's leukemia drug website. When a user clicked on the Facebook Share widget, a brief description of the drug and a link to the website for the drug was sent to the user's Facebook page for sharing with other Facebook users.

Although the website contained risk information for the drug, the FDA letter stated, "the inclusion of such a hyperlink is insufficient to mitigate the misleading omission of risk information from these promotional materials. For promotional materials to be truthful and non-misleading, they must contain risk information in each part as necessary to qualify any claims made about the drug."

3. Reporting Obligations

Although all companies bear the public relations risks that a discussion of their products or services in a public forum may generate negative comments, manufacturers of health products bear additional statutory reporting obligations if side effects of the product are discussed.

For example, in Canada, manufacturers of drugs must report any "serious adverse drug reaction" occurring in Canada, and any "serious unexpected adverse drug reaction" occurring outside Canada, within 15 days of receiving the information.

Health Canada guidelines specifically state that drug manufacturers "should regularly screen websites under their management or responsibility for potential adverse reaction case reports". Further, the guidelines state that the test for whether a case is "reportable" is the same for cases from the Internet as for cases obtained via other means.

Therefore, as long as the following minimum criteria are met, a company must report the case to Health Canada:

  • an identifiable reporter (source);
  • an identifiable patient;
  • a suspect product; and
  • an adverse reaction.

Although the rules may seem clear, it can sometimes be difficult to determine whether a case should be reported. For example, over the Internet, it is often unclear in which jurisdiction a patient is resident, and yet whether a reaction is reportable to Health Canada can be dependent on whether it occurred in Canada or elsewhere.

Further, the Health Canada guidelines state that "One or more of the following should automatically qualify a patient as identifiable: age or age category (e.g., adolescent, adult, elderly), gender, patient identification number, or reference to a 'patient'.

Given the broad parameters that qualify a patient as identifiable, a manufacturer may unintentionally make duplicate reports because it may be uncertain whether the same case is being discussed multiple times or whether multiple cases are being discussed.

Moving Forward with Caution

The three issues mentioned above highlight only a few of the concerns raised when drugs or medical devices are advertised using social media. Drug and device companies must take particular care to thoroughly assess any proposal involving social media and to consider how the proposal can best be structured to minimize any potential risk.

As part of the assessment, companies should remember that they will also need to be diligent in monitoring what transpires after the initiative is launched so they can respond immediately if required. If the social media initiative is structured appropriately, just as with the use of the drugs and devices themselves, the benefits can certainly outweigh the risks.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Oct 2016, Seminar, Toronto, Canada

Please join members of the Blakes Commercial Real Estate group as they discuss five key provisions of a commercial real estate purchase agreement that are often the subject of much negotiation but are sometimes misunderstood.

1 Nov 2016, Seminar, Toronto, Canada

What is the emotional culture of your organization?

Every organization and workplace has an emotional culture that can have an impact on everything from employee performance to customer or client satisfaction.

3 Nov 2016, Seminar, Toronto, Canada

Join leading lawyers from the Blakes Pensions, Benefits & Executive Compensation group as they discuss recent updates and legal developments in pension and employee benefits law as well as strategies to identify and minimize common risks.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.